Manufacturing, Biosimilars and Biobetters

May 7th 2025

As more originator biologics lose patent exclusivity in the next decade, a healthy biosimilars pipeline is necessary but requires market support.

September 8th 2024

Weighing development costs/resources and performance benefits is essential.

August 9th 2024

BioPharm International® spoke with Zara Bukhari, a PhD scholar at the University of the Pacific, Stockton, CA, and co-author of the peer-review research paper, Biosimilars Drug Development: Advances in Technologies from Molecule Design to Clinical Trials, published in the July/August 2024 issue, about process development for biosimilars.

March 2nd 2024

Despite a growing number of biosimilar approvals, market uptake remains a challenge.